Evidence map›Paper›PMID 21331080›Full record

ReviewNature reviews. Immunology2011

Immune cell regulation by autocrine purinergic signalling.

Wolfgang G Junger

Abstract readReview
In one paragraph

Review in Nature reviews. Immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 431 papers.

0numbers the graph read from it
0cells of the map it votes in
431citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

431 citing papers in PubMed.

  1. Review
  2. Tumor-associated CD19Nature communications · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. eATP sensing by the purinergic receptor PA2072 for allosteric modulation in intracellular c-di-GMP signaling.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Revisiting the critical roles of reactive microglia in traumatic brain injury.International journal of surgery (London, England) · 2025
    Review
  20. Article

371 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Wolfgang G JungerDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA. wjunger@bidmc.harvard.edu

Funding

Neutrophil activation and traumaR01GM060475 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JUNGER, WOLFGANG G · 2001 to 2016
$3.8M
Purinergic regulation of T cellsR01GM051477 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JUNGER, WOLFGANG G · 2003 to 2016
$2.5M
Purinergic receptors in inflammationR01AI080582 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI JUNGER, WOLFGANG G · 2009 to 2012
$1.4M
Autocrine control of neutrophil chemotaxisR01AI072287 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI JUNGER, WOLFGANG G · 2009 to 2010
$766k
HYPERTONIC SALINE AND IMMUNE FUNCTIONR29GM051477 · NIGMS · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI JUNGER, WOLFGANG G · 1996 to 2000
$116k
NIAID NIH HHS AI-072287NIAID NIH HHS AI-080582NIAID NIH HHS R01 AI072287NIAID NIH HHS R01 AI080582NIGMS NIH HHS GM-51477NIGMS NIH HHS GM-60475NIGMS NIH HHS R01 GM051477NIGMS NIH HHS R01 GM060475NIGMS NIH HHS R29 GM051477
6 · The paper itself

Abstract

Stimulation of almost all mammalian cell types leads to the release of cellular ATP and autocrine feedback through a diverse array of purinergic receptors. Depending on the types of purinergic receptors that are involved, autocrine signalling can promote or inhibit cell activation and fine-tune functional responses. Recent work has shown that autocrine signalling is an important checkpoint in immune cell activation and allows immune cells to adjust their functional responses based on the extracellular cues provided by their environment. This Review focuses on the roles of autocrine purinergic signalling in the regulation of both innate and adaptive immune responses and discusses the potential of targeting purinergic receptors for treating immune-mediated disease.

Indexed as

Adaptive ImmunityAdenosineAdenosine TriphosphateAnimalsAutocrine CommunicationChemotaxisHumansImmune ToleranceImmunity, InnateLeukocytesLymphocyte ActivationLymphocytesMacrophagesNod Signaling Adaptor ProteinsNucleoside Transport ProteinsPyrophosphatasesAdenosineAdenosine TriphosphateNod Signaling Adaptor ProteinsNucleoside Transport ProteinsPyrophosphatasesReceptors, PurinergicToll-Like Receptors

Identifiers

PMID21331080
PMCPMC4209705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.